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18 ABSTRACT: The neutrophilic serine protease proteinase 3 (PR3) is involved in inflammation and immune response and thus
19 appears as a therapeutic target for a variety of infectious and inflammatory diseases. Here we combined kinetic and molecular
20 docking studies to increase the potency of peptidyl-diphenyl phosphonate PR3 inhibitors. Occupancy of the S1 subsite of PR3 by
21 a nVal residue and of the S4−S5 subsites by a biotinylated Val residue as obtained in biotin-VYDnVP(O-C6H4-4-Cl)2 enhanced
22 the second-order inhibition constant kobs/[I] toward PR3 by more than 10 times (kobs/[I] = 73000 ± 5000 M
−1 s−1) as compared
23 to the best phosphonate PR3 inhibitor previously reported. This inhibitor shows no significant inhibitory activity toward human
24 neutrophil elastase and resists proteolytic degradation in sputa from cystic fibrosis patients. It also inhibits macaque PR3 but not
25 the PR3 from rodents and can thus be used for in vivo assays in a primate model of inflammation.
26 ■ INTRODUCTION
27 Polymorphonuclear neutrophil phagocytes are characterized by
28 the presence of abundant intracytoplasmic granules rich in
29 antimicrobial peptides and proteins involved in innate
30 immunity.1,2 Azurophilic granules also store four neutrophil
31 serine proteases (NSPs): proteinase 3 (PR3), elastase (NE),
32 cathepsin G (CG), and neutrophil serine protease 4 (NSP-4),
33 which are released into the environment in response to
34 inflammatory stimuli.1,3 An excess of proteases may be released,
35 however, during chronic inflammation which disrupts the
36 protease−protease inhibitor balance and accelerates proteolysis
37of the extracellular matrix.4,5 The administration of exogenous
38inhibitors targeting these proteases may thus be an excellent
39therapeutic strategy to fight inflammation.5,6 Although the total
40amount of PR3 in neutrophils is similar to that of NE or CG, its
41activity is by far less controlled by endogenous inhibitors.7
42Indeed, there is no specific endogenous inhibitor of human PR3
43(humPR3) and one of its more potent inhibitors, α-1-
44proteinase inhibitor (α1PI), interacts about 100 times less
45 rapidly with humPR3 than with humNE.7 Further, the
46 pathophysiological role of humPR3 is less well understood
47 than that of the related humNE and CG. Its function as
48 autoantigen in granulomatosis with polyangiitis8−10 and its
49 likely involvement in neutrophil apoptosis11 makes it different
50 from its closest homologue humNE.
51 humPR3 closely resembles humNE structurally and func-
52 tionally with a highly conserved catalytic triad (His57, Asp102,
53 and Ser195 residues (chymotrypsinogen numbering)) located
54 between two similar domains each comprising a six-stranded β-
55 barrel.12 Its pI, however, is somewhat less basic than that of
56 humNE.5,13 Several residues on the loops surrounding the
57 protease active site assist the catalytic process. Most
58 importantly, the backbone amide hydrogens of Gly193 and
59 Ser195 that define the oxyanion hole and are located near the
60 carbonyl group of the substrate’s scissile bond, stabilizing the
61 developing partial charge on the tetrahedral intermediate
62 during catalysis.14
63 The structural analysis of the active site of humPR3 and
64 humNE showed that the distribution of charged residues close
65 to the substrate binding site (99 loop, 60 loop, 37 loop, and
66 autolysis loop) of these two proteases differs notably.15 Thus,
67 humPR3 contains three charged residues Lys99, Asp61, and
68 Arg143 in the active site region.12 The S1 binding pocket of
69 humPR3 and humNE is hemispherical, therefore, both
70 preferentially accommodate small hydrophobic residues at the
71 P1 position (according to the nomenclature of Schechter and
72 Berger (Schechter and Berger, 1967)).7,13 The S2 subsite of
73 humPR3 differs from that of humNE by the presence of a
74 solvent accessible Lys at position 99, favoring accommodation
75 of negatively charged or polar P2 residues in the deep S2
76 subsite of PR3.12 The Leu99 residue in humNE makes the S2
77 pocket more hydrophobic. The Lys99 of humPR3 is conserved
78 in the PR3 of higher primates and many artiodactyls but not in
79 PR3 of New World monkeys and rodents, whereas the Leu99
80of humNE is highly conserved in many other species.7 This
81makes the PR3 specificity of these latter species different from
82that of humPR3 and explains that rodents are not an
83appropriate animal model for studies related to the biological
84activity of humPR3. Another critical residue that makes the
85specificities of humPR3 and humNE different is that at position
86217 in the vicinity of the S4 subsite, where an Ile in humPR3 is
87replaced by an Arg in humNE.16,17
88We have designed and synthesized selective peptidyl-
89diphenyl phosphonate inhibitors based on these structural
90differences between humPR3 and humNE using the sequence of
91an optimized peptide substrate of PR3.18 Phosphonate
92inhibitors are peptide-based transition state irreversible
93inhibitors which form transition-state-resembling complexes
94with serine proteases.19−21 The inhibition is initiated by the
95formation of a noncovalent enzyme−inhibitor complex, which
96upon the nucleophilic attack of the Ser195 on the phosphorus
97atom loses one aryloxy group, forming an initial, irreversible
98 f1covalent complex (Figure 1). Further aging followed by
99hydrolysis of a second ester group leads to the formation of
100an aged covalent protease−inhibitor complex stabilized by the
101oxyanion hole.19 Phosphonate inhibitors are chemically stable
102inhibitors that block selectively serine proteases at low
103concentration under acidic or neutral conditions.22 Phospho-
104nate inhibitors were designed and developed by anchoring of
105the serine trap to the recognition sequence derived from a
106peptidyl substrate of the target protease (Figure 1). These
107inhibitors which interact covalently with the Ser195 of the
108catalytic triad can also be used as activity-based probes (ABP)23
109to visualize membrane-bound or intracellular, proteolytically
110active, serine proteases.24 Several peptidyl-diphenyl phospho-
111nate inhibitors of humPR3 have been developed but all were
112more potent toward humNE25,26 until we synthesized the first
113selective chlorodiphenyl phosphonate humPR3 inhibitors, the
Figure 1. Design, structure, and mechanism of action of 1-aminoalkylphosphonate diaryl ester inhibitors. (A) General strategy of a substrate-based
approach for covalent inhibitors development. (B) Development of a peptidyl-phosphonate inhibitor. (C) Mechanism of serine proteases inhibition
by 1-aminoalkylphosphonate diaryl esters together with crystal structures of bovine trypsin (Protein Data Bank (PDB) 4I8G and 1MAY) and human
matriptase (PDB 3NCL) at different stages of aging process.
114 N-biotinylation of which allows using them ABP to visualize
115 active humPR3 in biological samples.18
116 Application of PR3 inhibitors as therapeutic tools requires
117 that they easily reach and interact with their target protease
118 with great specificity, they resist degradation during their
119 administration and in situ, and their half-life in the organism is
120 significant. Using inhibitors as therapeutic tools also requires
121 that a relevant animal model is available for preclinical studies.
122 In this work, we first designed and developed new biotin-
123 peptidylP(O-C6H4-4-Cl)2 inhibitors with improved potency of
124 action toward humPR3 to use them as versatile pharmacological
125 tools for assessing protease function in vivo. We focused on
126 improving the rate constant for inactivation (kobs/[I]) by
127 molecular docking trials and on analyzing structure−activity
128 relationships (SAR) to optimize efficacy at a very low dose and
129 thus make the resulting compound effective for a pharmaco-
130 logical application. Because PR3 from rodents retain a substrate
131 specificity that differs from that of human,27 we then looked for
132 a relevant in vivo model of inflammation and tested
133 phosphonate inhibitors on the PR3 from Macaca fascicularis.
134 ■ RESULTS
135 Stabilizing Properties of a Biotinylated N-Terminal P4
136 Residue in PR3 Substrates and Inhibitors. Replacing the
137 N-terminal acetyl group by biotin (Bt) in Ac-PYDAP(O-C6H4-
138 4-Cl)2 (1) to give Bt-PYDA
P(O-C6H4-4-Cl)2 (2) significantly
139 improved the kobs/[I] value
18 (4168 M−1 s−1 vs 154 M−1 s−1)
t1 140 (Table 1) and significantly improved the Ki value of the initial
t2 141 noncovalent complex (21 vs 3600 nM) (Table 2). Accordingly,
142 the substitution of the N-terminal acetyl group by a biotin in
143 the paranitroanilide (pNA) substrate Ac-PYDA-pNA increased
t3 144 the specificity constant kcat/Km by ∼6-fold (Table 3). We
145 employed a computational docking approach to explain how
146 biotin could modulate the interaction between Bt-PYDAP(O-
f2 147 C6H4-Cl)2 and the active site of PR3 (Figure 2A,B). The lowest
148 energy binding mode obtained in the docking studies of 2 with
149 humPR3 revealed that the biotin moiety is located in the S5
150 pocket limited by the Lys99, Phe166, Cys168, Arg177, and
151 Ile217 residues (Figure 2B). The entrance into this pocket is
152 guarded by the Lys99 side chain with its ε-amino group,
153 creating a hydrogen bonding with the carbonyl oxygen of the
154 Bt-Pro4 amide bond. This interaction would facilitate the
155 correct orientation of both Pro4 and biotin in the S4 and S5
156 binding sites, respectively. The arrangement of Phe166,
157Cys168, and Arg177 residues in the S5 subsite creates the
158cavity that accommodates the biotin heterocyclic rings (Figure
1592B). The stabilizing role of biotin was confirmed by introducing
160a polyethylene glycol [PEG]2 spacer between the P4 residue
161Pro and biotin (Bt-[PEG]2-PYDA
P(O-C6H4-4-Cl)2 (3), which
162resulted in a dramatic fall of the kobs/[I] (Table 1). The docking
163model shows that the length of the biotin moiety is optimal for
164the binding in the S5 pocket, and any spacer between the Pro4
165and biotin would not improve the interaction. A biotin at P5
Table 1. Rates of Inhibition of humPR3 and humNE by Peptide Phosphonates
proteases
kobs/[I] (M
−1 s−1)a
compd peptide phosphonate esters [I] μM humPR3 humNE
1 Ac-Pro-Tyr-Asp-AlaP(O-C6H4-4-Cl)2 2 154 ± 3
b ns
2 Bt-Pro-Tyr-Asp-AlaP(O-C6H4-4-Cl)2 0.06 4168 ± 553
# ns
3 Bt-[PEG]2-Pro-Tyr-Asp-AlaP(O-C6H4-4-Cl)2 0.6 274 ± 12 ns
4 Bt-Val-Tyr-Asp-AlaP(O-C6H4-4-Cl)2 0.025 17396 ± 835 ns
5 Bt-Leu-Tyr-Asp-AlaP(O-C6H44-Cl)2 0.15 4371 ± 652 ns
6 Bt-Ile-Tyr-Asp-AlaP(O-C6H4-4-Cl)2 0.15 8698 ± 658 ns
7 Bt-nLeu-Tyr-Asp-AlaP(O-C6H4-4-Cl)2 0.025 10361 ± 766 ns
8 Bt-nLeu(O-Bzl)-Tyr-Asp-AlaP(O-C6H4-4-Cl)2 0.1 1744 ± 164 ns
9 Bt-Pro-Tyr-Asp-AbuP (O-C6H4-4-Cl)2 0.1 4675 ± 438 ns
10 Bt-Pro-Tyr-Asp-nValP(O-C6H4-4-Cl)2 0.025 18642 ± 705 ns
11 Bt-Val-Tyr-Asp-nValP(O-C6H4-4-Cl)2 0.01 73258 ± 5342 ns
aValues are the means ± SD of three experiments; bValues were taken from ref 18. Definition of abbreviation: ns, not significant
Table 2. Rates of Inhibition of humPR3 by Peptide
Phosphonates
1
Ac-Pro-Tyr-Asp-AlaP(O-C6H4-4-Cl)2
Ki (nM) 3600 ± 425
k2 (min
−1) 0.08 ± 0.01
2
Bt-Pro-Tyr-Asp-AlaP(O-C6H4-4-Cl)2
Ki (nM) 21 ± 4.2
k2 (min
−1) 0.035 ± 0.01
11
Bt-Val-Tyr-Asp-nValP(O-C6H4-4-Cl)2
Ki (nM) 5.4 ± 0.14
k2 (min
−1) 0.15 ± 0.01
Table 3. Kinetics of Synthetic Substrate Cleavage by
humPR3 and humNE
proteases
kcat/Km (M
−1 s−1)a
pNA substrates [S] mM humPR3 humNE
Ac-Pro-Tyr-Asp-Ala-pNA 1 4201 ± 29.7b nh
Bt-Pro-Tyr-Asp-Ala-pNA 1 25080 ± 141.4 nh
Bt-Val-Tyr-Asp-Ala-pNA 1 34965 ± 99 nh
Bt-Val-Tyr-Asp-nVal-pNA 1 80510 ± 2973 nh
aValues are means ± SD of three experiments. bValue was taken from
ref 18. Definition of abbreviation: nh, not hydrolyzed
166 was thus retained for the construction of new inhibitors with a
167 modified peptidyl sequence.
168 Influence of the P4 Residue on the Inhibitory Activity
169 of Bt-PeptidylP(O-C6H4-4-Cl)2 Phosphonate Inhibitors.
170 The computational docking study showed that the P4 residue
171Pro in 2 was close to solvent accessible hydrophobic Trp218 in
172PR3 (Figure 2B). We replaced the P4 Pro by Val (4), Leu (5),
173Ile (6), and norleucine (nLeu) (7) to tentatively optimize the
174interaction with the PR3 hydrophobic patch build by residues
175Phe166, Ile217, Phe224, and possibly with Trp218. While Leu
176or Ile at P4 position decreased the inhibitory activity toward
177PR3, the presence of nLeu or Val improved the inhibitory
178activity by ∼2 and ∼4 times, respectively (Table 1).
179Accordingly, the specificity constant kcat/Km of the pNA
180substrate Bt-VYDA-pNA was also improved (Table 3).
181Whatever the substitution at P4 in phosphonate inhibitors
182was, the resulting compound retained no significant inhibitory
183activity toward humNE although this protease also prefers a
184hydrophobic residue at this position. Because the S4 subsite is
185composed mainly by side chains of Trp218 and Ile217 and the
186distinctly hydrophobic area (Phe166, Phe224) span beyond this
187position, we decided to probe the existence of interactions by
188substitution nLeu by nLeu(O-Bzl) at P4 in 7 (8). However, this
189resulted in more than 10 times lower kobs/[I] value (Table 1).
190Moreover, the molecular docking model did not confirm the
191interaction between nLeu(O-Bzl) and, as mentioned above, a
192distant hydrophobic area. In fact, the P4 side chain of 8 makes
193contact mainly with Trp218 (Figure 2C). The comparison with
194the 2 model (Figure 2B) indicates that the introduction of
195more sizable nLeu(O-Bzl) group at P4 does not alter the overall
196mode of binding but affects the placement of inhibitor
197backbone at the S4 subsite, thus preventing hydrogen bond
198formation between Lys99 and the carbonyl oxygen of the Bt-
199nLeu(O-Bzl) amide (Figure 1C).
200Influence of the P1 and P4 Residues on the Efficacy of
201Bt-PeptidylP(O-C6H4-4-Cl)2 Phosphonate Inhibitors. Un-
202like the S2 subsite of PR3 that preferentially accommodates
203negatively charged P2 residues and is thus essential to confer
204PR3 selectivity,15 the S1 subsite in PR3 may accommodate a
205variety of residues including norvaline (nVal) and aminobutyric
206acid (Abu) among the favorites. We substituted the P1 alanyl
207residue in the parent inhibitor (2) by Abu and nVal. Bt-
208PYDAP(O-C6H4-4-Cl)2 (2) and Bt-PYDAbu
P(O-C6H4-4-Cl)2
209(9) showed similar efficacy toward PR3 (Table 1). However,
210Bt-PYDnVP(O-C6H4-4-Cl)2 (10) was ∼4.5 times more potent
211than 2.
212As expected, the substitution of Pro by Val at P4 in 10 (11)
213significantly improved the kobs/[I] value, providing the best
214inhibitor of the series with a kobs/[I] = 73000 ± 5000 M
−1 s−1.
215This 20-fold increase as compared to 1 resulted from a decrease
216in the Ki value of the initial equilibrium between PR3 and Bt-
217VYDnVP(O-C6H4-4-Cl)2 (11) and an increase of the first-order
218rate constant k2 producing the final covalent complex (Table
2192). Combining Val at P4 and nVal at P1 in the pNA substrate
220Bt-VYDnV-pNA also significantly increased the specificity
221constant toward PR3 (Table 3).
222The computational docking approach employed to examine
223the interaction between Bt-VYDnVP(O-C6H4-4-Cl)2 and
224 f3humPR3 (Figure 3A) revealed that for the lowest energy
225pose the overall mode of enzyme−inhibitor binding resembles
226the one obtained for Bt-PYDAP(O-C6H4-4-Cl)2 (2). The biotin
227aliphatic chain interacts with the hydrophobic surface of S5
228subsite, while the biotin rings extend into the terminal cavity of
229this subsite in the manner observed with Bt-PYDAP(O-C6H4-4-
230Cl)2. For both models, the P4 residue of inhibitor is located at
231the narrow subsite with the Trp218 on one side and the Lys99
232on the other. Therefore, increased inhibitory potency observed
233for derivatives with Val instead of Pro at P4 may be due to an
Figure 2. Proposed putative model of 1 (A), 2 (B), and 8 (C) binding
to the active site of humPR3. The solvent-accessible surface area of the
active site in humPR3 (PDB 1FUJ12) was made transparent to allow
the visualization of the residues in stick representation. The single-
letter code of residues in the vicinity of the active site is indicated in
black. Residues are labeled following the numbering of chymotrypsin.
The residues of the catalytic triad H57, D102, and S195 are
underlined. The carbon atoms of PR3 and the compounds are
shown in white and cyan, respectively. The oxygen, nitrogen, sulfur,
and phosphorus atoms are colored in red, blue, yellow, and orange,
respectively.
234 improved flexibility of this region upon enzyme−inhibitor
235 binding. The ε-amino group of Lys99 forms hydrogen bonds
236 with Bt-Val4 amide carbonyl oxygen as well as Asp2 carboxyl
237 group. Additionally, quantum chemical calculations of inter-
238 action energy revealed that Lys99 residue contributes the most
239 to binding of Bt-Val4 portion of the inhibitor, as the value of
240 the interaction energy due to the presence of this particular
t4 241 residue amounts to −16.6 kcal/mol (Table 4). Attracting
242 interactions between Bt-Val4 tail of 11 and PR3 residues were
243 also found for Phe166 and Val216 (−3.8 and −1.6 kcal/mol,
244 respectively). Except for Ile217, Trp218, and Phe215 residues
245 that appear to exert unfavorable influence in terms of Bt-Val4
246 binding, the remaining PR3 residues promote Bt-Val4 binding
247 with the interaction energy not exceeding −1 kcal/mol. It
248 should be pointed out that excessively repulsive interactions
249 associated with some residues probably arise from the lack of
250 quantum chemical refinement of the binding poses obtained
251 from docking simulations, as empirical force field based
252 methods often employed throughout the docking procedures
253 tend to introduce shortened intermolecular contacts.28 The
254 location of the biotin rings into the S5 binding site prevents
255 recognition of all these compounds by extravidin by Western
256 blotting (WB) under nondenaturating/reducing conditions
257 (not shown).
258 Stability of Bt-VYDnVP(O-C6H4-4-Cl)2 (11) in a Bio-
259 logical Environment. We then tested the properties of 11 in
260 sputa from patients with cystic fibrosis (CF) and measured
261 humPR3 activities of sputum samples before and after
262incubation with 11 (5−10 nM final). A 1 nM humPR3
263concentration was estimated in these samples by comparison
264with the rate of hydrolysis of the ABZ-VADnVADYQ-EDDnp
265substrate. Cleavage of the humPR3 substrate was totally
266inhibited after incubation for 20 min at 37 °C with 11 (Figure
Figure 3. Inhibition of humPR3 and stability of 11 in the cell free supernatants of sputa from CF patients. (A) Proposed putative model of 11 in
humPR3 active center. (B) Inhibition of PR3 in a representative CF sputum supernatants. The volume of CF sputum was adjusted to give final
concentrations of PR3, 1 nM. Diluted samples were incubated with 11 (5 and 10 nM final) for 20 min at 37 °C. Inhibition was monitored by
measuring the residual activity of PR3 on ABZ-VADnVADYQ-EDDnp (20 μM). Purified PR3 (1 nM) was used as control. (C) Selective labeling of
PR3 activity in CF sputum and neutrophil lysate. Samples (10 μg of total protein) were incubated for 20 min at 37 °C with 11 (50 nM), and the
mixtures were analyzed by WB using extravidin-peroxidase. (D) HPLC profile of the 11 after a 120 min incubation time with samples showing the
stability of the inhibitor in sputa from cystic fibrosis patients. Similar results were found in three independent experiments.
Table 4. MP2/6-31+G(d) Interaction Energya between
Amino Acid Residues Representing humPR3 or macPR3
Binding Site and Bt-Val4 Fragment of 11
binding energy
humPR3 residues substituted macPR3 residues humPR3 macPR3
Lys99 −16.6 −10.0
Phe165 Leu −0.3 −0.4
Phe166 Leu −3.8 −0.8
Cys168-Cys182 −0.8 −1.2
Asn98-Arg177-Asn180 −0.8 0.3
Pro178 Thr 0.1 0.2
Phe192 −0.1 0.0
Phe215 5.5 24.2
Val216 −1.6 −2.6
Ile217 12.3 15.4
Trp218 Arg 7.6 6.4
Gly219 Glu −0.3 −3.3
Phe224 −0.6 −0.9
Pro225 −0.6 −0.7
Phe227 −0.8 −1.6
aIn units of kcal/mol.
267 3B), while humNE activity remained unchanged (not shown).
268 Inhibitor 11 was also successfully used to selectively label
269 proteolytically active humPR3 in CF sputum and in a lysate of
270 purified human blood neutrophils (Figure 3C). Additionally,
271 we showed that inhibitor 11 preserved full inhibitory activity
272 and resisted degradation when it was mixed with CF sputum
273 for 2 h at 37 °C as shown by high performance liquid
274 chromatography (HPLC) (Figure 3D).
275 Characterization and Inhibition of Macaque PR3
276 (macPR3) by Phosphonate Inhibitors in Purified Neu-
277 trophil Lysates. Protein sequences alignment of humPR3 and
278 macaque PR3 (Macaca fascicularis) shows that they are 86%
279 identical, and they differ by only 28 residues. Their substrate
280 binding site is very similar and critical residues Lys99, Arg143,
281and Ile217 that confer high selectivity to humPR3 are conserved
282 f4in macPR3 (Figure 4A,B). We thus hypothesized that, unlike
283PR3 homologues in rodents, macPR3 will be efficiently
284inhibited by peptide-based phosphonate inhibitors designed
285for humPR3. All phosphonate inhibitors of humPR3 reported
286above were able to inhibit macPR3. As observed for humPR3,
287biotinylated inhibitors were more efficient than acylated
288inhibitors at inhibiting macPR3 (1, Ac-PYDAP(O-C6H4-4-
289Cl)2, kobs/I = 55 ± 4 M
−1 s−1; 2, Bt-PYDAP(O-C6H4-4-Cl)2,
290kobs/I = 1985 ± 215 M
−1 s−1; 11, Bt-VYDAP(O-C6H4-4-Cl)2,
291kobs/I = 36480 ± 3350 M
−1 s−1), but their overall potency was
292somewhat lesser than that recorded for humPR3 (Table 1). The
293inhibition of macPR3 with 11 is shown in Figure 3C.
Figure 4. Inhibition of macPR3 by inhibitor 11. (A) Human and macaque sequence alignment. The sequences of humPR3 (1FUJ.pdb)12 and
macPR3 (Macaca fascicularis, GenPept: XP_005587394.1) were aligned using Protein BLAST with default parameters. Similar amino acid residues
are indicated in blue and remaining substitutions are in red. Active center residues are indicated by asterisk. The residues included in quantum
chemical calculations are indicated in bold. The sequence numbering according 1FUJ.pdb file. Sequence alignment of humPR3 and macPR3 show
190/221 (86%) identical positions, 200/221 (90%) positives, and no gaps. (B) Proposed putative model of 11 in macPR3 active center. (C)
Inhibition of PR3 by 11 in macaque neutrophil lysates. The volume of lysates was adjusted to give final concentrations of PR3, 1 nM. Diluted
samples were incubated with 11 (10 nM final) for 20 min at 37 °C. Inhibition was monitored by measuring the residual activity of PR3 on ABZ-
VADnVADYQ-EDDnp (20 μM) as in Korkmaz et al.52 Purified humPR3 (1 nM) was used as control. Similar results were found in three
independent experiments.
294 To further examine binding preferences of 11 against human
295 and macPR3 proteases and interaction energy values between
296 Bt-Val4 fragment of the inhibitor and PR3, binding sites were
297 compared for particular residues representing S5 binding
298 pocket (Table 4). Lys99, the most important residue promoting
299 inhibitor binding of humPR3, seems to exert also the largest
300 influence in terms of the analogous interaction with macPR3.
301 However, the corresponding binding energy value is less
302 significant in the case of macPR3−inhibitor complex compared
303 to interaction with humPR3 (−10.0 versus −16.6 kcal/mol;
304 Table 4). Another substantial difference in binding energy
305 values concerns repulsive interaction due to the presence of
306 Phe215 residue. Unfavorable interaction characterizing
307 humPR3−inhibitor complex (5.5 kcal/mol) amounts to 24.2
308 kcal/mol in the corresponding macPR3 Phe215−inhibitor
309 complex (Table 4). The remaining repulsive interactions
310 associated with Ile217 and Trp218 are retained in the case of
311 macPR3 inhibition despite the substitution of Trp218 by an
312 arginine residue. Interestingly, three out of five substitutions
313 that involve PR3 residues in the vicinity of the Bt-Val4 inhibitor
314 fragment do not seem to modulate binding potency of 11
315 against human and macPR3 homologues. The more substantial
316 changes related to residue substitution accompany the change
317 of Phe166 to leucine and Gly219 to glutamate. However, these
318substitution-induced changes in binding energy cancel each
319other out, as the interaction energy value increased by 3 kcal/
320mol as a result of the Phe166Leu substitution is decreased by
321the same extent upon the Gly219Glu substitution. Overall, the
322differences in inhibitor binding by human and macPR3 appear
323to arise from decreased attractive interaction with Lys99 and
324increased repulsion with Phe215 residues. Because conforma-
325tion and spatial placement of these two residues is essentially
326identical in both complexes, the observed changes in binding
327energy appear to arise from slightly different positioning of the
328Bt-Val4 portion of the inhibitor molecule due to substitutions
329present in the macPR3 S4 and S5 subsites.
330■ DISCUSSION
331Evidence has now accumulated that the neutrophilic serine
332protease humPR3 acquired specific pathophysiological proper-
333ties and nonredundant functions in spite of its close
334resemblance to humNE.5,29 Indeed, it slightly differs from the
335latter by its spatiotemporal localization,30 its substrate
336specificity, and its sensitivity to natural inhibitors, all factors
337that taken together explain its specific function as an
338autoantigen in granulomatosis with polyangiitis and its probable
339involvement in cell apoptosis.6,11 Controlling the proteolytic
340activity of this protease specifically, e.g., by protease inhibitors,
Figure 5. Scheme showing the synthesis of peptidyl di(chlorophenyl)-phosphonate ester inhibitors.
341 is a means to better understand its biological function, but all
342 physiological inhibitors of humPR3 preferentially target
343 humNE. It is only recently that we and others began to
344 synthesize chemical inhibitors that selectively target the
345 humPR3 active site.7 The specificity of serine proteases is
346 determined by their substrate binding sites that are located on
347 both sides of the cleaved peptide bond. We used a substrate-
348 based approach to develop serpin-like irreversible inhibitor
349 (SerpinB1(STDA/R) and azapeptide (azapro-3), a reversible
350 inhibitor that selectively inhibits PR3.31 Such inhibitors,
351 however, cannot be used as ABP to visualize active humPR3
352 in biological fluids or in cells and tissues. We recently
353 developed a series of N-terminally biotinylated peptidyl-
354 diphenyl phosphonate inhibitors that allow the detection of
355 humPR3 at the cell surface and inside cells.18 These are
356 transition state analogues, irreversible inhibitors that interact
357 with nonprime subsites of the target serine protease to form
358 “phosphonylated” enzymes. Protease−inhibitor complexes
359 show a remarkable stability due to the similarity of the
360 phosphorus atom with the tetrahedral intermediate formed
361 during peptide bond hydrolysis. Although chemically stable in
362 blood samples, their pharmacological use requires that they
363 interact rapidly with their target protease to be effective at low
364 concentrations. We have further investigated the nonprime
365 specificity of humPR3 to develop more potent di-
366 (chlorophenyl)-phosphonate ester inhibitors that could be
f5 367 used as molecular probes to control humPR3 activity (Figure
f5 368 5).
369 We previously showed that the S2/P2 specificity was
370 essential to discriminate between humPR3 and its close
371 homologue humNE.15 Lys99 in humPR3 is a key residue to
372 explain the preferential accommodation of negatively charged
373 or polar residues at P2.5,7 Thus, selective humPR3 substrates or
374 peptide sequences selectively cleaved by humPR3 all contain a
375 negatively charged or a polar residue at position P2.6
376 SerpinB1(STDA/R) and azapro-3 that selectively inhibit
377 humPR3 contain a negatively charged residue (Asp) at P2
378 position. However, humPR3 may accommodate different
379 residues at P1 and P4 as confirmed by molecular modeling
380 studies. The S1 binding pocket of humPR3 is more accessible
381 and spacey than that of humNE and can accommodate not only
382 the Ala or Abu side chain but also methionine, valine, and nVal,
383 which was shown experimentally and by computational
384 docking. In a recent study using single-residue mutant of
385 humPR3 with Arg at position 217 (PR3I217R), we showed that
386 Ile217 located in the neighborhood of the S4 subsite pocket
387 significantly affects the substrate specificity of humPR3.18 The
388 docking models performed in this study using phosphonate
389 inhibitors indicate also that the solvent accessible surface of the
390 S4 subsite is limited by Trp218 and Ile217 on one side. The
391 latter two residues are most likely responsible for the binding
392 preference toward aliphatic side chains at P4 and Lys99, which
393 is located on the opposite side of the S4 subsite, determines
394 cooperation between S2 and S4 via hydrogen bonding.
395 Introduction of a Val and a nVal at P4 and P1 positions,
396 respectively, in the biotinylated humPR3 inhibitor previously
397 reported, Bt-PYDAP(O-C6H4-4-Cl)2 (2), enhanced the kobs/[I]
398 value toward humPR3 by ∼20-fold. This was probably because
399 the substitution of Pro4 by Val4 improved the flexibility of the
400 inhibitor, favoring the formation of hydrogen bonds between
401 the ε-amino group of Lys99 and Bt-Val4 amide carbonyl
402 oxygen as well as Asp2 carboxyl group. These hydrogen bond
403interactions are in agreement with previously described
404cooperation observed between S2 and S4 subsites.18
405Biotin at the N-terminal of P4 residue in phosphonate
406inhibitors and peptidyl-pNA substrates displays stabilizing
407properties. General orientation, size, and hydrophobic character
408of humPR3 S5 pocket that accommodates N-terminal biotin is
409similar to that of humNE crystallized in complex with a
410phosphonate inhibitor bearing a nLeu(O-Bzl) moiety at P4 and
411called an “exopocket”, an extension of the S4 subsite.32 The
412docking models from this study show that the terminal cavity of
413the humPR3 S5 pocket formed by Phe166, Cys168, and Arg177
414accommodates the biotin heterocyclic rings, while the hydro-
415phobic surface of Ile217 interacts with the biotin aliphatic
416chain. The location of the biotin rings into the S5 binding site
417prevents recognition of the biotinylated inhibitors by extravidin
418by WB under nondenaturating conditions (not shown). Only
419the five-carbon aliphatic chain of biotin participates in the
420stabilization of the inhibitor within the humPR3 active site as
421deduced from the observation that a phosphonate inhibitors
422with a same peptide sequence but bearing only a N-terminal
423five-carbon aliphatic chain enhanced the inhibition rate as well
424as whole biotin.18 Analysis of the docking models suggests that
425the substantial impact of N-terminal biotin binding with S5
426subsite on the overall inhibitory potency might be connected
427with the limited size of S4 binding site. The main contribution
428to the binding energy at this position is provided by Lys99,
429forming the hydrogen bond with the backbone of the inhibitor
430and stabilizing the biotin moiety in proper orientation. Because
431of the narrow character of S4 subsite and the presence of
432Trp218 and Ile217 on the opposite site of Lys99, there is a
433strong preference for small, hydrophobic residues at P4
434position. Therefore, the introduction of more sizable side
435chain such as nLeu(O-Bzl) may influence proper stabilization of
436the compound at P4 subsite, resulting in decreased inhibitory
437potency.
438One of the challenges when designing preclinical studies for
439PR3 is to select a relevant animal model. We previously showed
440that PR3 from rodents differs from humPR3 both in terms of
441substrate specificity, which preclude the use of substrate-derived
442phosphonate inhibitors and of subcellular distribution because
443there is no constitutive expression of PR3 at the neutrophil
444surface of rodent neutrophils.27,33 We therefore used a
445nonhuman primate model to investigate the substrate
446specificity of neutrophilic PR3 and its sensitivity to
447phosphonate inhibitors developed against humPR3. In view of
448the highly conserved primary amino acid sequence of macPR3
449implying a very similar specificity as with humPR3, macPR3
450cleaved the humPR3 substrate at the same site34 and this
451activity was inhibited by all phosphonate inhibitors of humPR3
452used in this study. WB analysis of the macaque neutrophil
453lysate using an anti-humPR3 antibody revealed the presence of
454a single band of 26 kDa in the neutrophil lysate with no
455glycosylated forms.34 A single band of 75 kDa was revealed
456after the lysate was incubated with human α1PI, indicating that
457macPR3 had formed an irreversible complex with the serpin. In
458keeping with this observation, the proteolytic activity toward
459the humPR3 substrate in the lysate was inhibited by α1PI and
460by the PR3-specific serpinB1(STDA/R) inhibitor35 (not
461shown). The identification of proteolytically active macPR3 in
462the neutrophil lysate was further confirmed by electrophoresis
463under nondenaturing/nonreducing conditions using the ABP
464Bt-[PEG]66-PYDAP(O-C6H6-4-Cl)2 and streptavidin-peroxi-
465dase staining.34 We found similar level of active PR3 in lysates
466 of purified human and macaque neutrophils by kinetics and
467 immunobloting assays. The macaque model thus appears as
468 relevant animal model for in vivo studies.
469 ■ CONCLUSION
470 Targeting the humPR3 active site by specific inhibitors has
471 become evidence as soon as it has been established that it was
472 not a redundant protease mimicking humNE and that its
473 proteolytic activity was poorly controlled by physiological
474 inhibitors. We have optimized here the structure of peptidyl
475 phosphonate inhibitors by coupling molecular modeling studies
476 with kinetic analyses, and we obtained molecular probes to
477 follow the fate and further investigate the function of PR3 both
478 in vitro and in vivo. The potency and selectivity of the
479 inhibitors developed here let us suppose that they are suitable
480 therapeutic tools for fighting inflammatory and/or infectious
481 diseases where the role of humPR3 has been clearly identified
482 or even only suspected.
483 ■ EXPERIMENTAL SECTION
484 Materials. humNE (EC 3.4.21.37) was obtained from Athens
485 Research and Technology (USA). The fluorescence resonance energy
486 transfer (FRET) substrates ABZ-VADnVADYQ-EDDnp/ABZ-
487 APEEIMRRQ-EDDnp and chromogenic para-nitroanilide substrates
488 synthesized by Genecust (Dudelange Luxembourg). IGEPAL CA-630
489 (NP40) was purchased from Sigma-Aldrich (St. Louis, MO, USA).
490 Synthesis of Peptidyl-phosphonate Inhibitors. All reagents
491 and solvents were obtained from commercial sources and were used
492 without purification.
493 All final compounds were purified to >95% purity HPLC system
494 (Jasco LC System, Jasco, Japan) equipped with Supelco Wide Pore C8
495 column (8 mm × 250 mm) and ultraviolet−visible (UV−vis, 226 nm)
496 and fluorescent detectors (excitation 320 nm, emission 450 nm). A
497 linear gradient from 10 to 90% of B within 40 min was applied (A,
498 0.1% TFA in water; B, 80% acetonitrile in A).
499 The nuclear magnetic resonance spectra (1H, 31P and 13C) were
500 recorded on either a Bruker Avance DRX-300 (300.13 MHz for 1H
501 NMR, 121.50 MHz for 31P NMR), a Bruker Avance 600 MHz (600.58
502 MHz for 1H NMR, 243.10 MHz for 31P NMR, and 101.12 MHz for
503
13C NMR) or Bruker AVANCE III 700 MHz (700.67 MHz for 1H
504 NMR) spectrometer. Chemical shifts are reported in parts per million
505 (ppm) relative to a tetramethylsilane internal standard. Mass spectra
506 were recorded using a Biflex III MALDI TOF mass spectrometer
507 (Bruker, Germany). The cyano-4-hydroxycinnamic acid (CCA) was
508 used as a matrix. High resolution mass spectra (HRMS) were acquired
509 either on a Waters Acquity Ultra Performance LC, LCT Premier XE,
510 or Bruker micrOTOF-Q II mass spectrometer.
511 Cbz-Protected 1-Aminoalkylphosphonate Diaryl Esters (General
512 Procedure). The first step in the synthesis of the phosphonic
513 analogues of Ala, nVal, and Abu was the preparation of tri(4-
514 chlorophenyl)phosphite from 4-chlorophenol and phosphorus tri-
515 chloride.36 Briefly, phosphorus trichloride (10 mmol) was added to 4-
516 chlorophenol (30 mmol) dissolved in acetonitrile (50 mL) and the
517 mixture refluxed for 6 h. The volatile elements were removed in a
518 vacuum, and the resulting crude phosphite, a yellow oil, was used
519 directly in an amidoalkylation reaction. It was mixed with benzyl
520 carbamate (12 mmol) and an appropriate aldehyde: acetaldehyde,
521 butyraldehyde, or propionaldehyde (12 mmol) and refluxed in acetic
522 acid for 3 h (Oleksyszyn’s method37).
523 Deprotection of Cbz Group (General Procedure). The Cbz
524 protecting group was removed by incubation with 33% hydrobromic
525 acid in acetic acid (2 h). The volatile components were removed under
526 reduced pressure, and the products were crystallized from methanol/
527 diethyl ether to give target compounds as hydrobromide salts.
528 Benzyl (1-(Bis(4-chlorophenoxy)phosphoryl)ethyl)carbamate (12,
529 Cbz-AlaP(O-C6H4-4-Cl)2). 12 was prepared using the general method
530 described above and crystallized from methanol to yield a white solid
531(56%). 1H NMR (300.13 MHz, CDCl3-d1, ppm): δ 7.43−6.97 (m,
53214H), 5.22−5.08 (m, 2H), 4.74−4.37 (m, 1H), 1.56 (dd, J = 18.2, 7.4
533Hz, 3H). 31P NMR (121.50 MHz, CDCl3-d1, ppm): δ 19.56 (s).
13C
534NMR (101.12 MHz, DMSO-d6, ppm): δ 156.16, 156.11, 151.14,
535151.05, 150.84, 150.74, 137.20, 134.14, 131.91, 131.88, 128.87, 128.46,
536128.34, 126.15, 126.03, 121.13, 121.09, 120.99, 119.99, 119.73, 66.48,
53745.30, 43.73, 15.52. HRMS: calcd for (C22H20Cl2NO5P)H
+ 480.0534,
538found 480.0533.
539Benzyl (1-(Bis(4-chlorophenoxy)phosphoryl)propyl)carbamate
540(13, Cbz-AbuP(O-C6H4-4-Cl)2). 13 was prepared using the general
541method described above and crystallized from methanol to yield a
542white solid (19%). 1H NMR (300.13 MHz, CDCl3-d1, ppm): δ 7.45−
5436.99 (m, 13H), 5.14 (d, J = 10.7 Hz, 1H), 5.24−5.06 (m, 2H), 4.50−
5444.33 (m, 1H), 2.20−2.03 (m, 1H), 1.87−1.64 (m, 1H), 1.11 (t, J = 7.3
545Hz, 3H). 31P NMR (121.50 MHz, CDCl3-d1, ppm): δ 18.31 (s).
13C
546NMR (101.12 MHz, DMSO-d6, ppm): δ 156.85, 156.81, 149.45,
547149.35, 149.12, 149.03, 137.34, 130.35, 130.28, 130.03, 129.86, 129.65,
548128.88, 128.44, 128.32, 128.01, 122.94, 122.90, 122.67, 122.63, 117.44,
54966.43, 51.27, 49.72, 22.46, 22.42, 11.16, 11.01. HRMS: calcd for
550(C23H22Cl2NO5P)H
+ 494.0691, found 494.0699.
551Benzyl (1-(Bis(4-chlorophenoxy)phosphoryl)butyl)carbamate
552(14, Cbz-nValP(O-C6H4-4-Cl)2). 14 was prepared using the general
553method described above and crystallized from methanol to yield a
554white solid (20%). 1H NMR (600.58 MHz, CDCl3-d1, ppm): δ 7.42−
5556.68 (m, 13H), 5.24−5.15 (m, 2H), 5.11 (d, J = 12.2 Hz, 1H), 4.57−
5564.44 (m, 1H), 2.07−1.95 (m, 2H), 1.67−1.39 (m, 2H), 1.02−0.93 (m,
5573H). 31P NMR (243 MHz, CDCl3, ppm): δ 18.47 (s). 13C NMR
558(101.12 MHz, DMSO-d6, ppm): δ 156.85, 156.76, 156.71, 149.45,
559149.35, 149.11, 149.02, 137.32, 130.36, 130.29, 130.05, 129.87, 129.65,
560128.88, 128.45, 128.34, 122.95, 122.91, 122.67, 122.63, 117.44, 66.44,
56149.23, 47.66, 30.63, 19.10, 18.95, 13.68. HRMS: calcd for
562(C24H24Cl2NO5P)Na
+ 530.0667, found 530.0670.
563Bis(4-chlorophenyl) (1-Aminoethyl)phosphonate Hydrobromide
564(15, HBr×H2N-Ala
P(O-C6H4-4-Cl)2). 15 was prepared using the general
565method described above and crystallized from diethyl ether to yield a
566white solid (97%). 1H NMR (300.13 MHz, DMSO-d6, ppm): δ 8.85
567(s, 3H), 7.57−7.44 (m, 4H), 7.36−7.16 (m, 4H), 4.45−4.24 (m, 1H),
5681.55 (dd, J = 18.3, 7.2 Hz, 3H). 31P NMR (121.50 MHz, DMSO-d6,
569ppm): δ 16.49 (s). 13C NMR (101.12 MHz, DMSO-d6, ppm): δ
570148.63, 148.61, 148.53, 148.52, 130.57, 130.54, 130.53, 129.62, 123.02,
571122.98, 122.94, 117.45, 43.50, 41.93, 13.96, 13.93. HRMS: calcd for
572(C14H14Cl2NO3P)H
+ 346.0167, found 346.0172.
573Bis(4-chlorophenyl) (1-Aminopropyl)phosphonate Hydrobro-
574mide (16, HBr×H2N-Abu
P(O-C6H4-4-Cl)2). 16 was prepared using
575the general method described above and crystallized form diethyl ether
576to yield a white solid (83%). 1H NMR (300.13 MHz, DMSO-d6,
577ppm): δ 8.87 (s, 2H), 7.67−7.13 (m, 8H), 4.21 (dt, J = 13.6, 6.8 Hz,
5781H), 2.24−1.74 (m, 2H), 1.11 (t, J = 7.4 Hz, 3H). 31P NMR (121.50
579MHz, DMSO-d6, ppm): δ 16.50 (s).
13C NMR (101.12 MHz, DMSO-
580d6, ppm): δ 148.56, 148.47, 130.58, 130.54, 123.05, 123.01, 122.97,
581122.93, 48.80, 47.26, 22.01, 21.99, 10.81, 10.72. HRMS: calcd for
582(C15H16Cl2NO3P)H
+ 360.0318, found 361.1123.
583Bis(4-chlorophenyl) (1-Aminobutyl)phosphonate hydrobromide
584(17, HBr×H2N-nVal
P(O-C6H4-4-Cl)2). 17 was prepared using the
585general method described above and crystallized from diethyl ether
586to yield a white solid (89%). 1H NMR (300.13 MHz, DMSO-d6,
587ppm): δ 8.88 (s, 2H), 7.49−7.27 (m, 8H), 4.25 (dt, J = 13.9, 7.0 Hz,
5881H), 2.06−1.78 (m, 2H), 1.71−1.46 (m, 2H), 0.90 (t, J = 7.3 Hz, 3H).
589
31P NMR (121.50 MHz, DMSO-d6, ppm): δ 16.55 (s).
13C NMR
590(101.12 MHz, DMSO-d6, ppm): δ 148.59, 148.58, 148.49, 148.48,
591130.58, 130.53, 123.06, 123.02, 122.96, 122.92, 47.40, 45.85, 30.39,
59230.36, 19.02, 18.92, 14.06. HRMS: calcd for (C16H18Cl2NO3P)H
+
593374.0474, found 375.1931.
594The peptides were synthesized manually by the solid-phase method
595using Fmoc chemistry. The following amino acid derivatives were
596used: Fmoc-Pro, Fmoc-Val, Fmoc-Leu, Fmoc-Ile, Fmoc-nLeu, Fmoc-
597nLeu(O-Bzl), Fmoc-Tyr(tBu), and Fmoc-Asp(OtBu). The protected
598derivative of the C-terminal amino acid residue, Fmoc-Asp(OtBu), was
599attached to the 2-chlorotrityl resin (substitution of Cl 1.46 mequiv/g)
600(Calbiochem-Novabiochem AG, Switzerland) in the presence of an
601 equimolar amount of diisopropylethylamine (DIPEA) under anhy-
602 drous conditions in dichloromethane (DCM) solution. A peptide
603 chain was elongated in consecutive cycles of deprotection (20%
604 piperidine in dimethylformamide (DMF)/n-methylpyrrolidone
605 (NMP) (1:1, v/v) with 1% Triton X-100) and coupling (DIC/
606 HOBt chemistry; 3 equiv of protected amino acid derivatives were
607 used). A 10-fold molar excess of N-acetylimidazole in DMF was used
608 for acetylation of the N-terminus. Bt-[PEG]2-Pro-Tyr-Asp-Ala
P(O-
609 C6H4-4-Cl)2 was synthesized via coupling of the Fmoc-PEG2 to the
610 amino group of terminal Pro residue. The N-terminal biotin group was
611 conjugated using a 5-fold molar excess of biotin and 1,3-
612 diisopropylcarbidiimide (DIC) as the coupling agent in anhydrous
613 DMSO for 6 h at 30 °C. The synthesized peptides were cleaved from
614 the resin with TFE/hexane/acetic acid (1:6:1, v/v/v).
615 Fully protected peptides were dissolved in DMF and their carboxyl
616 groups were activated with DIC and coupled with HBr×H2N-Ala
P(O-
617 C6H4-4-Cl)2, HBr×H2N-Abu
P(O-C6H4-4-Cl)2, or HBr×H2N-
618 nValP(O-C6H4-4-Cl)2 in DMF in the presence of DIPEA. The mixture
619 was stirred for 6 h, and the DMF was removed under reduced
620 pressure. The resulting compounds were suspended in trifluoroacetic
621 acid (TFA)/phenol/triisopropylsilane/H2O (88:5:2:5, v/v/v/v) for 2
622 h to remove side chain protecting groups.
623 The crude peptides were purified by HPLC on a Beckman Gold
624 System (Beckman, USA) with an RP Kromasil-100, C8, 5 μm column
625 (8 mm × 250 mm) (Knauer, Germany). The solvent systems were
626 0.1% TFA (A) and 80% acetonitrile in A (B). Either isocratic
627 conditions or a linear gradient were applied (flow rate 3.0 mL/min,
628 monitored at 226 nm). The purity of the synthesized peptides was
629 verified on RP Kromasil 100, C8, 5 μm column (4.6 mm × 250 mm)
630 (Knauer, Germany). The peptides were eluted with a linear gradient of
631 the above solvent system (10%−90% B) for 30 min, flow rate 1 mL/
632 min, monitored at 226 nm. HPLC retention times and 1H NMR
t5 633 spectra of final phosphonate peptide inhibitors are shown in Table 5
634 and Supporting Information, respectively. Mass spectrometric analysis
635 of the inhibitors (Table 5) was done on a MALDI MS (a Biflex III
636 MALDI-TOF spectrometer, Bruker Daltonics, Germany) using a CCA
637 matrix.
638 Enzymatic Studies: Free humPR3 and humNE Were Titrated
639 with α1PI.38 kcat/Km determination: The specificity constants kcat/Km
640 for peptidyl-pNA substrates were determined under first-order
641 conditions.38 The cleavage of the substrates (1 mM final) was
642 monitored by measuring the absorbance of liberated pNA at 410 nm
643 on the spectrophotometer (Versamax microplate reader, Molecular
644 Devices, Sunnyvale, CA, USA). Measurements were carried out at 37
645 °C in buffer 50 mM HEPES, 0.75 M NaCl, 0.05% NP40, pH 7.4. Final
646 protease concentrations were 0.01−1 μM.
647 kobs/[I] determination: The inactivation of proteases by phospho-
648 nate inhibitors (substrate analogue inhibitors) in the presence of the
649 substrate by competition for the enzyme-binding site was measured by
650the method of Tian and Tsou.39 Product formation in the presence of
651an irreversible inhibitor approaches an asymptote in this system, as
652described by log([P∞] − [P]) = log[P∞] − 0.43A[Y]t.
653• where [P∞] is the concentration of product formed at time
654approaching infinity, [P] is the concentration of product at time
655t, [Y] is the inhibitor concentration, and A is the apparent
656inhibition rate constant in the presence of the substrate. A is
657given by A = k+o/(1 + K
−1[S])
658• where k+o is the rate constant for association of the inhibitor
659with the enzyme, K−1 is the inverted Michaelis constant, and
660[S] the substrate concentration. The apparent inhibition rate
661constant A is the slope of a plot of log([P∞] − [P]) against t, to
662give the second-order rate constant of inhibition k+o.
663The rates of inhibition of purified humPR3, macPR3 (in purified
664blood neutrophil lysates), and purified humNE were measured using
665FRET substrates (ABZ-VADnVADYQ-EDDnp (10 μM final) and
666ABZ-APEEIMRRQ-EDDnp (10 μM final) in 50 mM HEPES, 0.75 M
667NaCl, and 0.05% NP40, pH = 7.4; excitation wavelength, 320 nm;
668emission wavelength, 420 nm; Spectramax Gemini (Molecular
669Devices, Sunnyvale, CA, USA). Final protease concentrations were 1
670nM.
671Ki and k2 determination: We monitored the extent of protease
672inhibition at several time points for a different inhibitor concentrations
673[I]. The observed rate constant for inhibition, kobs, at each
674concentration was determined from the slope of a semilogarithmic
675plot of inhibition versus time. The kobs values were replotted against
676inhibitor concentration and fitted to a hyperbolic equation, kobs =
677k2[I]/(Ki + [I]), to obtain values for Ki and k2.
40
678Detection of PR3 in Biological Fluids. CF sputa (50 μg
679proteins) were incubated with 11 (50 nM final) for 20 min at 37 °C in
680PBS. The reaction was stopped by adding 1 volume of 2× SDS
681reducing buffer and heating at 90 °C for 5 min. The components of
682the mixture were separated by SDS-PAGE, 12% NaDodSO4-
683polyacrylamide gel electrophoresis under denaturing conditions.
684They were transferred to a nitrocellulose (Hybond)-ECL (Enhanced
685Chemiluminescence) membrane at 4 °C.
686Extravidin Peroxidase Detection. Free sites on the membrane were
687blocked with 3% bovine serum albumin (BSA) in 0.1% Tween in PBS
688for 90 min at room temperature (RT). Membranes were then given
689two quick washes with PBS-Tween 0.1% and incubated for 2 h at RT
690with extravidin horseradish peroxidase (HRP) (Sigma-Aldrich)
691(diluted 1/4000 in 3% BSA in PBS-Tween 0.1%). The extravidin-
692HRP treated membrane was washed (3 × 10 min) with PBS-Tween
6931% and then incubated with HRP substrate for 3 min. Reactive bands
694were identified by chemiluminescence (ECL Kit).
695Immunodetection. Free sites on the membranes were blocked by
696incubation with 5% nonfat dried milk in PBS-0.1% Tween for 90 min
697at RT. They were washed twice with PBS-Tween 0.1% and incubated
698overnight with a rabbit primary anti-PR3 antibody (1:700, EPR6277
699Abcam), followed by a goat antirabbit IgG secondary antibody
700(1:7000, A9169 Sigma). These membranes were then washed and
701processed as above.
702Purification and Lysis of M. fascicularis Neutrophils. Female
703cynomolgus monkeys (Macaca fascicularis) (approximately 3 years old
704and weighing 4−5 kg) were obtained from a commercial supplier. All
705animal experiments and procedures were approved by the local animal
706experimentation ethics committee (Comite ́ d’et́hique Val de Loire
707(APAFIS no. 2982-20151105293399v6)). Five mL of peripheral blood
708samples were collected in lithium−heparin tubes from a femoral vein.
709Animals were kept under spontaneous ventilation during anesthesia
710with ketamine (10 mg/kg). The monitoring included pulse-oximetry
711and heart rate recording. Intravenous access was secured with a 22G
712canula on the legs. Anticoagulated whole blood was layered onto Ficoll
713density gradient and centrifuged. The purified neutrophils (>98%) in
714suspension was treated with H2O for 30 s to lyse red blood cells. The
715neutrophils were then lysed in Hepes 50 mM, NaCl 0.15 M, NP40
7160.5%, pH 7.4, and the supernatant was collected and stored at −80 °C.
717Chromatographic Procedures and Peptide Analysis. Inhibitor
71811 (75 μM final) was incubated with the cell free supernatants of sputa
Table 5. Calculated and Observed Massesa and HPLC
Retention Times of Synthesized Inhibitors 1−11
compd calculated mass (Da) found mass (Da) retention time (min)
1 763.56 764.67 12.36
2 947.82 948.91 13.12
3 1266.18 1266.23 10.05
4 949.83 951.01 12.56
5 963.86 964.79 12.47
6 963.86 964.92 12.51
7 963.86 964.88 12.42
8 1055.95 1057.08 13.57
9 961.54 962.50 13.43
10 975.87 976.95 13.20
11 977.89 977.97 12.58
aThe obtained molecular weights represent pseudomolecular ions (M
+ H)+.
719 from CF patients at 37 °C for 2 h in PBS. FRET substrate ABZ-
720 VADnVADYQ-EDDnp15 (20 μM final) was incubated with humR3
721 and macaque neutrophil lysate supernatant (10−500 nM) at 37 °C in
722 50 mM HEPES, 0.75 M NaCl, and 0.05% NP40, pH = 7.4. The
723 proteins were precipitated with absolute ethanol (4 volumes). The
724 supernatant containing the peptides were dried under vacuum and
725 dissolved in 200 μL of 0.01% trifluoroacetic acid (v/v), then
726 fractionated by Agilent Technology 1200 series HPLC system (Agilent
727 Technology, CA, USA) on a C18 column (2.1 mm × 30 mm, Merck
728 Millipore) at a flow rate of 0.3 mL/min with a linear gradient (0−90%,
729 v/v) of acetonitrile in 0.01% trifluoroacetic acid over 40 min. Eluted
730 peaks were monitored at 220 nm.
731 Molecular Modeling. Molecular docking was performed in order
732 to explain interactions of Ac-PYDAP(O-C6H4-4-Cl)2 (1), Bt-
733 PYDAP(O-C6H4-4-Cl)2 (2), Bt-nLeu(O-Bzl)YDA
P(O-C6H4-4-Cl)2
734 (8), and Bt-VYDnVP(O-C6H4-4-Cl)2 (11) with humPR3 and
735 macPR3. As a receptor, the crystal structure of humPR3 (1FUJ.pdb)12
736 was selected. The same structure was used as a template for macPR3
737 3D model obtained by means of automated homology modeling
738 server, SWISS-MODEL.41 For the docking studies, inhibitor molecules
739 were used as a peptidyl phosphonic acids [Ac-PYDAP(OH)2, Bt-
740 PYDAP(OH)2, Bt-VYDnV
P(OH)2, and Bt-nLeu(O-Bzl)YDA
P(OH)2]
741 instead of di(chlorophenyl)-phosphonate esters, as this is the form
742 present in the “aged” protein−inhibitor complex. The ligand models
743 were optimized using the MM2 force field (as implemented in
744 ChemBio3D 12.0),42 while the atom types and protonation of all
745 structures were set using SPORES.43 The docking was carried out
746 using the Protein−Ligand ANT System (PLANTS v. 1.2) with
747 PLANTSCHEMPLP scoring function.
44−46 The protein molecules were
748 treated as fixed with the binding site center defined at a carbonyl
749 oxygen of Ser214 and the binding site radius of 15 Å. The distance
750 constraints were set up to increase the preference of interaction
751 between (a) inhibitor phosphorus atom and the hydroxide oxygen of
752 protease Ser195 (distance range was defined between 2.2 and 4.0 Å),
753 (b) the terminal carbon of Ala/nVal side chain of ligand P1 position
754 and enzyme S1 binding pocket set at γ-carbon of Ile190 (distance
755 range: 5.5−6.5 Å for Ala and 2.2−5.0 Å for nVal), (c) Asp γ-carbon of
756 the inhibitor (P2 position) and PR3 ε-amine nitrogen of Lys99
757 (distance range 2.0−5.0 Å),and (d) ligand P3−P4 amide bond
758 nitrogen and Val216 carbonyl oxygen of the receptor (distance range
759 2.0−5.0 Å). The lowest energy binding poses obtained from docking
760 simulations were then employed in quantum chemical calculations of
761 interaction energy between PR3 amino acid residues and Bt-Val4
762 fragment of inhibitor to explain the differences in activity of 11 toward
763 human and macaque enzyme. humPR3 or macPR3 binding site was
764 represented by all amino acid residues within 6 Å of inhibitor fragment
765 considered herein. Because of the presence of disulfide bridge in the
766 vicinity of inhibitor molecule, covalently linked Cys168 and Cys182
767 residues were included as a single monomer. Arg177 was found to be
768 hydrogen-bonded to Asn98 and Asn180 residues. To avoid disrupting
769 the hydrogen bonding network, these three residues were also
770 considered as a monomer. The remaining 15 PR3 residues were
771 included separately. The dangling bonds resulting from cutting the
772 residues out of the protein scaffold were saturated with hydrogen
773 atoms. PR3−inhibitor binding energy was calculated in a pairwise
774 manner at the second-order Møller−Plesset level of theory (MP2)
775 using 6-31+G(d) basis set47−49 and counterpoise correction to
776 eliminate basis set superposition error.50 Quantum chemical
777 calculations were performed in Gaussian09 program.51
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